Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2033

Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.

Patents
1,330

Quick answer

1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8614208

    Fused heterocyclic ring derivative and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8613900

    Nanostructured transition metal oxides useful for water oxidation catalysis

    The Regents of the University of California · Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8614304

    Immunogenic peptides and methods of use for treating and preventing cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Serives · Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8618134

    Method and composition for treating a serotonin receptor-mediated condition

    VANDA PHARMACEUTICALS INC. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8617815

    Molecules with effects on cellular development and function

    The Regents of the University of California · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8618095

    2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8617538

    Mesodermal-like cell population for treating ischemia in mammals

    The Board of Regents of the University of Texas System · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8617132

    Bioresorbable embolization microspheres

    Regents of the University of Minnesota · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8617549

    Bispecific nanobodies as a therapeutic for alzheimer's disease

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8618259

    Polymer-factor VIII conjugate compositions

    Nektar Therapeutics · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8618167

    Methods of attenuating cognitive deficits with sulfonyl fluorides

    The Board of Regents of the University of Texas System · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8617600

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Supernus Pharmaceuticals, Inc. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8617530

    Polymer conjugates of opioid antagonists

    Nektar Therapeutics · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8618106

    Protein kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8618152

    Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases

    Vertex Pharmaceuticals Incorporated · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8618290

    HSP90 inhibitors

    Takeda Pharmaceutical Company Limited · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8618331

    Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8617557

    Antibody fusion with IL-12 proteins with disrupted heparin-binding activity

    The Regents of the University of California · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8618058

    Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity

    Soricimed Biopharma Inc. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8618080

    Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines

    OM PHARMA · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8618090

    Inhibitors of the plasmodial surface anion channel as antimalarials

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8618074

    GPCR enhanced neuroprotection to treat brain injury

    The Board of Regents of the University of Texas System · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8618096

    Prodrug compositions and methods for using the same in treating cancer and malaria

    The Regents of the University of California · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8618110

    Compositions and methods for apoptosis modulators

    VM Discovery Inc. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8618131

    Biphenyl derivatives

    Theravance, Inc. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8618130

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    ACADIA Pharmaceuticals Inc. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8618107

    Pyridone and aza-pyridone compounds and methods of use

    GILEAD CONNECTICUT, INC. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8618142

    Process for the preparation of roflumilast

    TAKEDA GMBH · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8618270

    Oligonucleotide analog and method for treating flavivirus infections

    Sarepta Therapeutics, Inc. · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8616429

    Structure containing wound treatment material

    Covidien LP · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8617143

    Therapeutic agent delivery systems and devices

    The Regents of the University of California · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8617532

    Therapeutic use of interferon-polymer conjugates

    PHARMAESSENTIA CORPORATION · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8618324

    Composition and method for making oligo-benzamide compounds

    The Board of Regents of the University of Texas System · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. EP 2678011

    ANTITUMORIGENE KOMBINATON, DIE CABAZITAXEL UND CISPLATIN UMFASST

    AVENTIS PHARMA SA [FR] · Granted Wed Jan 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Dec 27 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2033?

1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.